for me to know for others to guess
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OTCN 1st dumped 750k @0013 @ 13:26:35 3 seconds prior to moving the Ask down to 0013
OTCN drops back down to 0013 w/ 10k @ 13:26:38
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/trades
OTCN drops back down to 0013 w/ 10k @ 13:26:38
Authorized Shares 4,500,000,000 08/29/2023
Outstanding Shares 3,324,582,767 08/29/2023
Restricted 1,116,449,724 08/29/2023
Unrestricted 2,208,133,043 08/29/2023 >14,285,804
Held at DTC 2,157,685,216 08/29/2023 >65,655,412
YTD/DTC >599,360,305
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172611969&txt2find=Outstanding
Outstanding Shares 3,310,297,053 08/11/2023 >67,242,714
Restricted 1,116,449,724 08/11/2023
Unrestricted 2,193,847,329 08/11/2023 >67,242,714
Held at DTC 2,092,029,804 08/11/2023 >15,873,016
YTD/DTC>533,704,893
Aug 24, 2023 — The meaning of IRREFUTABLE is impossible to refute : incontrovertible
OTCN 0019 10k @ 8:22;09 OTCN 0015 10k @ 9:30:01 OTCN 0013 10k @ 10:07:57
OTCN bidding 001 all week (today 110k)
Enjoy your weekend & family
Authorized Shares 1,498,000,000 08/14/2023
Outstanding Shares 978,056,643 08/14/2023
Restricted 144,454,314 08/14/2023
Unrestricted 833,602,329 08/14/2023
Held at DTC 828,470,482 08/14/2023
Transfer Agent Verified Share data displayed on www.otcmarkets.com alongside a "Transfer Agent Verified" logo has recently been verified by the company’s transfer agent as reliable and trustworthy. This data is also disseminated through OTC Markets Group's market data feeds to investors and broker-dealers.
The Transfer Agent Verified Shares Program provides investors current and reliable share data. The program enables stock transfer agents to report their clients' share data, including authorized and outstanding shares, to OTC Markets Group on a regular basis via a secure, electronic file transfer.
MJLB 0.00035 0.00015 (75.00%) Volume: 298,316,726
Ultrack Systems Inc (PK)
0.00035 0.00015 (75.00%) Volume: 298,316,726
Day Range: 0.0002 - 0.00045
Bid: 0.0003
Ask: 0.0004
Last Trade Time: 2:41:38 PM EDT
Total Trades: 146
OTCN BKdown to 0014 @ 13:41:43 w/same volume
Volume 9,428,821 when OTCN moved to 0019
OTCN 10K 0013 @ 10:28:17 OTCN 10K 0014 10:44:46 OTCN 10k 0013 @10:49:18 after dumping 1,161,538 13s OTCN 10k 0014 @ 11:07:50 OTCN 10k 11:53:45 after dumping 476,698 OTCN 10k 0014 12:35:50 after 580k shares bought @ 13 OTCN 85k 0019 13:11:12
Volume 9,428,821 when OTCN moved to 0019
OTCN 10k .0017 @ 8:30:42 10k .0016 @ 9:30:04 10k .0015 @ 9:57:11 after dumping 939,239 15s
btw https://restem.com/ is up & running
https://www.prweb.com/releases/RESTEM_and_JAR_of_Hope_Foundation_Announce_Strategic_Partnership_and_Clinical_Trial_Launch_of_Next_Generation_Cell_Therapy_for_Patients_with_Duchenne_Muscular_Dystrophy/prweb18866576.htm
https://www.prnewswire.com/news-releases/fda-approves-covid-19-trial-after-successful-emergency-use-of-umbilical-stem-cells-from-restem-301059158.html
btw Dixon trying to insert himself into said Court Case I personally appreciate as there is now legal paperwork w/ Dixon admitting to his Ongoing P3 ________s
Case: 23-2054 Document: 12-1 Page: 1 Filed: 07/31/2023
Timothy G. Dixon
4093 Oceanside Blvd., Suite B
Oceanside, CA, 92056 ZG/3 JI.'L 3 ! P |: 32
Ph: 760-295-7208
Em: timdixon@tsoimail.com
Restem, LLC,
UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT
Plaintiff-Appellant
23-2054
Jadi Cell, LLC,
Defendants-Appellees
MOTION FOR LEAVE TO FILE BRIEF
AND BRIEF OF AMICICURIAE
TIMOTHY G. DIXON
MOTION FOR LEAVE TO FILE AMICI BRIEF
Pursuant to Federal Rule of Appellate Procedure 29(a) and Federal Circuit Rule 29(a), Amici
Timothy 0. Dixon moves the Court for leave to file the attached Brief Amici Curiae in support of
upholding the Final Written Decision of the Patent Trial and Appeal Board ("PTAB"). The proposed
brief is attached to this Motion. In support of this Motion, Amici state as follows:
1. I, Timothy G. Dixon declare as follows: I am over 18 years of age, CEO and chairman of
Therapeutic Solutions International, Inc., and its majority shareholder, as well as co-author of twenty-
three patent applications stemming from the patent, U.S. Patent No. 9,803,176 B2 ("the ' 176 patent")
at the heart the underlying Inter Paries Review ("IPR") (IPR2021-01535) and subject matter of the
appeal before this Court.
Page 1of3
Motion for Leave to File Amicus
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-1 Page: 1 Filed: 07/31/2023 (1 of 9)
2. I have personal knowledge of each fact stated herein except as to those matters stated as
knowledge based on information and belief, and as to those matters, I am informed and believe them to
be true and correct.
3. Therapeutic Solutions International, Inc. ("TSOI") is a Nevada Corporation that is publicly
traded on OTC Markets and is the exclusive worldwide license holder of use of the ' 176 patent for all
lung indications and CTE ("Chronic Traumatic Encephalopathy") and TBI ("Traumatic Brain Injury")
indications for the brain.
Proposed Amici
4. Leave to file a brief as amici curiae should be granted when "the amici have stated an 'interest
in the case,' and it appears that their brief is 'relevant' and 'desirable,'" such as when "it alerts the
merits panel to possible implications of the appeal." [Neonatology Assocs., P.A. v. C.I.R., 293 F.3d
128, 133 (3d Cir. 2002) (Alito, J.) (quoting Fed. R. App. P. 29(a)(3)); see also id. at 132 ("The criterion
of desirability set out in Rule 29(b)(2) is open-ended, but a broad reading is prudent.").]
5. Proposed Amici submits that the amicus brief collects background and factual references that
merit judicial notice and will provide a perspective that may benefit the Court and warrants their
participation as amici.
6. At the time of filing of this Motion for leave to file the amicus curiae brief, attorneys for the
Plaintiff have not consented to the filing of this amici brief.
7. At the time of filing of this Motion for leave to file the amicus curiae brief, attorneys for the
Defendant-Appellees have not consented to the filing of this amici brief.
8. While most of the amici who file in the Supreme Court and the courts of appeals do so with the
parties* consent, I believe that consent is now freely given in large part because it is thought that leave
to file would be granted in any event if consent were withheld. This point is made with respect to the
Supreme Court in Joseph D. Kearney and Thomas W. Merrill. The Influence of Amicus Curiae Briefs
on the Supreme Court, 148 U. Pa. L.Rev. 743, 762 (2000), and I believe that the same generally holds
true in the courts of appeals as well. [Neonatology Associates, P.A. v. C.I.R, 293 F.3d 128, 132 n.l
(3d Cir. 2002)].
///
Page 2 of3
Motion for Leave to File Amicus
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-1 Page: 2 Filed: 07/31/2023 (2 of 9)
9. Further, pursuant to Federal Rule of Appellate Procedure 29(a)(6) and Federal Circuit Rule
29(a)(6), amicus curiae briefs are due "no later than 7 days after the principal brief of the party being
supported is filed." This Court's June 22, 2023, Order directed Entry of Appearance is due on
07/06/2023. Certificate of Interest is due on 07/06/2023. Docketing Statement is due on 07/06/2023.
Certified List is due on 08/01/2023, but no party briefs have yet been filed, nor did the Court address
the timing of amicus filings. As a result, the Rules governing the timing for filing an amicus brief are
met.
10. Moreover, the attached amicus brief does not respond directly to arguments in the parties'
briefs, but rather provides insight into the prior Inter Parties Review as evidenced in the transcripts,
including inconsistent statements and factual inaccuracies, as well as possible undisclosed conflicts of
interest. As a result, it is not "responsive briefing" so much as it is background and factual information
that may benefit the Court in its appellate review.
For these reasons, Amici respectfully requests that the Court grant this Motion for Leave to File a Brief
Amici Curiae and accept the attached brief for filing.
Respectfully Submitted,
I
Timothy G. Dixon
Page 3 of3
Motion for Leave to File Amicus
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-1 Page: 3 Filed: 07/31/2023 (3 of 9)
Timothy G. Dixon
4093 Oceanside Blvd., Suite B
Oceanside, CA, 92056
Ph: 760-295-7208
Em: tsitgd@gmail.com
ED
31 P |:32
/¦ !
UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT
Restem LLC,
Plaintiff-Appellant
V. 23-2054
Jadi Cell LLC,
Defendants-Appellees
AMICUS CURIAE BRIEF OF TIMOTHY G. DIXON
THE UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT
1. I, Timothy G. Dixon aver as follows: I am over 18 years of age, CEO, Chairman of the Board
of Therapeutic Solutions International, Inc., and its majority shareholder, as well as being a co-author
of twenty-three patent applications stemming from the patent, U.S. Patent No. 9,803,176 B2 ("the ' 176
patent") at the heart the underlying Inter Partes Review ("IPR") (IPR2021-01535) and subject matter
of the appeal before this Court.
2. I have personal knowledge of each fact stated herein except as to those matters stated as
knowledge based on information and belief, and as to those matters, I am informed and believe them to
be true and correct.
///
1 of 6
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-2 Page: 1 Filed: 07/31/2023 (4 of 9)
3. Therapeutic Solutions International, Inc. ("TSOI") is a Nevada Corporation that is publicly
traded on OTC Markets, and is the exclusive worldwide license holder of use of the ' 176 patent for all
lung indications and CTE ("Chronic Traumatic Encephalopathy") and TBI ("Traumatic Brain Injury")
indications for the brain, and unfettered use, the drug master file, and master cell bank one for
JadiCells, the mesenchymal stem cells at issue and subject matter of this appeal.
4. Amici Timothy G. Dixon ("Dixon") submits this Amicus Curiae brief ("Amicus Brief) in
support of upholding the Final Written Decision of the Patent Trial and Appeal Board ("PTAB").
Amici submits that the Amicus Brief collects and describes background and factual references,
particularly as to motive and truthfulness of the parties in this appeal that merit judicial notice and will
provide a perspective that may benefit the Court and warrants their participation as amici and
presentment of this Amicus Brief.
5. Moreover, the Amicus Brief does not purport to respond directly to arguments in the Parties'
briefs, but rather provides insight into testimony given in the IPR, as evidenced in the transcripts,
including inconsistent statements and factual inaccuracies, as well as potential undisclosed conflicts of
interest of key witnesses and the Parties. As a result, it is not a "responsive briefing" so much as it is
background and factual information that may benefit the Court in its appellate review.
6. To wit, on or about October 24,2022, amici caused to be filed on behalf of TSOI a Form 8-K
with exhibits on the SEC's EDGAR site publicly disclosing the genesis of issues that arose involving
the Parties and witnesses to this appeal, specifically the Principal Investigator in a Phase l/2b Clinical
Trial at the University Miami, Dr. Camillo Ricordi, M.D. ("Ricordi") and key witness, Dr. Amit N.
Patel ("Patel"), inventor and patent holder of the '176 Patent at issue, key witness, and sole member of
Jadi Ceil LLC ("Jadi"), Appellees, as well as Restem LLC ("Restem"), Party and Appellant. [Please
see link below:
https://www.sec.gOv/ix7doc-/Archives/edgar/data/l 419051/000149315222029460/form8-k.htm1
7. The Form 8-K includes references to the depositions of Ricordi and Patel taken by counsel for
the Appellant and Appellee, and amici believes that certain facts testified to or materially relevant to
the IPR were either factually misstated, intentionally misleading, or material information withheld in
order to hide relationships and important information. Although amici believes that the PTAB reached
2 of 6
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-2 Page: 2 Filed: 07/31/2023 (5 of 9)
the correct decision, Appellants attempt to overturn the Final Written Decision are disingenuous and
made with motives that are not in the interest of justice or based on sound scientific reasoning.
8. In late November of 2021 amici became aware of the Inter Parties Review ("IPR") in Restem
LLC V. Jadi Cell, LLC through a social media post. Jadi Cell LLC, by virtue of the exclusive,
worldwide. Patent License Agreement ("EPLA") effective since February 9, 2021, had an obligation to
inform amici and TSOI of any challenges to the patent underlying EPLA, yet failed to do so until
nearly 6 months after the filing of the IPR by Appellant Restem.
9. On September 27, 2022, Patel was deposed in the matter of Restem LLC vs. Jadi Cell LLC. On
Pg. 77 of his transcript, Patel states he was offered $15 million dollars for JadiCells approximately 2
years ago, which would have been the August/September of 2020 timefi-ame. On pages 78 and 79 of
the transcripts, Patel' sworn testimony states that the offer that preceded TSOI's was "left up in the air
due to the IPR. That's what was stated by the lawyers."
10. This is practical impossibility as the IPR was not filed by Restem until September 29, 2021,
two weeks to the day after Jadi entered into the lung EPLA clarifying agreement of the 2/9/2021
convertible promissory note and license. In other words, a $15 Million license agreement was entered
into with TSOI and not "left in the air" as stated by Patel due to the filing of the IPR.
11. Dr. Patel is asked (on page 80 of his transcript) how much TSOI paid Jadi Cells [for its
exclusive license for lung indications], and Dr. Patel responded, "hundreds of thousands." Again, this
is incorrect and a gross misstatement as the Convertible Promissory Note, EPLA, and later the
Settlement Agreement, clearly states Jadi received $15,000,000 worth of TSOI stock at a fixed price of
$0.1004. This is of extreme importance that Dr. Patel was in the process of clearing their $15,000,000
worth of TSOI stock and depositing with a broker at the very time his deposition was being taken.
12. On August 26, 2022, Ricordi, was deposed. On page 13 of his transcript, he is asked if he has
had any communication with Jadi Cell LLC (i.e.. Dr. Patel as the LLC is a single-member LLC alter
ego) about his deposition and under oath states the following:
"No, I didn't. I didn't communicate about this procedure or the deposition. I've been
communicating in the past because this trial has been halted and we had all kind of
difficulties moving forward to identify standing sources because when everyone —
3 of 6
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-2 Page: 3 Filed: 07/31/2023 (6 of 9)
we had a Phase III trial approval FDA like a year ago or around a year ago and still we
have been unable to move forward because when people come close and they see that
there is a legal proceeding, they run in the opposite direction. I guess they don't want to
get involved. So practically we had very good results from the — spectacular results
from the Phase I/IIA trial and then we obtained permission to move for a Phase III trial
multisite and we were stuck and unable to save life and just witness the — COVID-19
to continue to unfold, but we were unable to help patients."
13. This is factually inaccurate and Ricordi knew it was inaccurate when he provided the sworn
testimony. On March 24, 2022, University of Miami ("UM"), and TSOI, entered into an Asset
Transfer and License Agreement which stated "Within ten (10) days of the Effective Date, 1) TSOI
shall make an initial payment of two hundred thousand dollars ($200,000) to UM; 2) Within six (6)
months of the Effective Date, TSOI shall make a second payment of one million eight hundred
thousand dollars ($1,800,000) (at the completion of the primary endpoint of the phase 2b/3 clinical
trial specified in the IND or (ii) one (1) year from the Effective Date), and 3) TSOI shall make a final
payment of two million dollars ($2,000,000). In turn, upon FDA approval of TSOI as Sponsor, TSOI
will replace UM as Sponsor, receive all trial doses, and intends to appoint James Veltmeyer, MD,
Chief Medical Officer as Principal Investigator.".
14. On March 28, 2022, Ricordi sent a letter to the FDA on behalf of UM stating that the IND has
been transferred to TSOI and that TSOI is the new owner of IND 19757. On March 28, 2022, Dr.
Thomas Ichim also sent a letter notifying the FDA of the IND transfer on behalf of TSOI, and on April
1, 2022, TSOI received notice from the FDA that the IND had officially been transferred.
15. Knowing all the above, Ricordi states that right up to August 2022, "we have been unable to
move forward because when people come close and they see that there is a legal proceeding, they run
in the opposite direction." It cannot reasonably be argued that the IPR has ever interfered with the
IND moving forward. Furthermore, when Ricordi provided his sworn statement in his deposition he
knew these statements were untrue.
16. Amici believes the following to be one possible explanation for the blatant untruths and
motivations behind them.
4 of 6
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-2 Page: 4 Filed: 07/31/2023 (7 of 9)
17. Jadi not only failed to notify TSOl in a timely manner of the filing of the IPR as was their
obligation under the EPLA, but consistently failed to communicate or provide progress reports of the
litigation. Most egregious, Jadi failed to inform amici or TSOI of the prior (current) relationship
between Ricordi and Restem. Amici had to learn of it through its own research.
18. On page 15 of Ricordi*s transcript he is asked about affiliations, advisory boards, institutions
etc., that he is involved in, and he provides a list of people and entities. Notably, Ricordi failed to
disclose his own relationship with Restem, which includes using Restem's mesenchymal stem cell in at
least 3 patients, as well as an article published on Restem's website, and at least three (3) scientific
papers Ricordi has co-authored with scientists from Restem. Oddly, the lawyer representing Restem
doesn't seem to know that his client has a long-standing working relationship with Ricordi and UM.
Amici wonders at the likelihood of that. Even more odd is the fact that this failure to disclose a
relationship that likely rises to a conflict of interest has not been corrected in the records, even though
Ricordi amended his deposition at the bequest of some unknown attorney to say the "aliquots" in
question came from the 176' patent.
19. On or about August 18, 2021, a long-time requested meeting occurred involving Ricordi, Patel,
Dixon, and others via a Zoom conference call wherein Ricordi expressed surprise and "claimed" this
was the first time he was hearing about TSOI and their exclusive world-wide patent license agreement
("EPLA") with Jadi Cell LLC ("Jadi"). Unsurprisingly, Ricordi's reactions to TSOI's presence was
unnerving for Dixon given how long the EPLA was in existence and the parties' established
relationships, let alone the many updates provided by Patel of the FDA review of the Phase III IND
application. Why Patel and Jadi kept TSOI's existence Ricordi, if true, is a mystery that continues
today. TSOI later discovered that on August 12,2021, just days before this meeting, Ricordi, on UM
Letterhead sent to the FDA a "Letter of Authorization" (LOA) for Arugula Sciences LLC to utilize
data that TSOI owns the exclusive rights to. Neither Patel the Licensor, nor Ricordi the letter writer
has ever informed TSOI of this infringement.
20. On Pg. 30 of the Ricordi transcript the lawyer for Restem asks "Q. Okay. But you're saying that
you don't have any financial connection to any company that uses cells claimed by the '176 Patent?" to
which Ricordi responds:
5 of 6
Case No. 23-2054
Date Filed 6/22/2023
Case: 23-2054 Document: 12-2 Page: 5 Filed: 07/31/2023 (8 of 9)
"No. As a matter of fact, I was invited by Neil Re-all-tin (phonetic) in Dallas that has a
facility with MSG that I thought had intention to work with Jadi Cells for some
application. But then he told me that when they found out that there are this legal things
or issues unresolved, they prefer to keep their respectful (INAUDIBLE). So I think
they're keeping their own sourced cells. So I'm not aware where Jadi Cell may be using
cells for other trials."
21. We know that the person he is referencing is actually Neil Riordan ("Riordan"), who is in
reality an alter ego of Arugula Sciences LLC. Ricordi, Neil Riordan, and Keith March of Restem have
all published scientific papers together, conducted clinical research together, and all have ongoing
working relationships that were never disclosed to the IPR Panel of Judges.
22. While none of this goes to the essence of whether or not the PTAB reached the correct decision
as to patentability claims, amici Dixon believes pointing out the above factual inaccuracies and failure
to disclose important relationships may shed light on the true motivation for filing the IPR and this
appeal; namely, because TSOI already obtained an EPLA for the ' 176 patent that includes the lung, a
crucial organ for any intravenous use of JadiCells, and because prior attempts at wresting the license
away from TSOI failed, invalidation of the patent, particularly Claim 1, was the only avenue remaining
to the parties involved.
Respectfully Submitted,
Timothy G. Dixon, Amici
https://www.tradinghours.com/mic/s/otcn 4the week so far
TSOIPR 9:30:00 OTCN LowersAsk0013 w/10k 10:30:00
https://www.businesswire.com/news/home/20230821767236/en/
OTCN to 0014 @ 11:26:38
OTCN to 0019 @ 14:20:18
Just yesterdays 8/21/22 facts!
8/22/233 OTCN drops 0015 ask to 0014 @ 9:56:33 nice EOD finish
8/23/23 OTCN @ 0800:03 @ 0018
OTCN 0017 10k @ 9:30:01
OTCN 10k 0016 @ 09:47:43
OTCN bidding 001 08:13:31 (been there all week)
OTCN 0017 @ 10:21:08
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/trades
OTCN back to 0016 w/ 10k @ 10:28:07
OTCN after a dump of 15s 10k 0017 @ 10:50:18
Could today be back to deuce day
CommonCents 2wonder what his like(s) mightB
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172434313&txt2find=Weiss
TSOI
Therapeutic Solutions International Inc (PK)
0.0016
0.00025 (18.52%)
Volume: 9,217,459
Day Range: 0.00135 - 0.0016
Last Trade Time: 3:58:57 PM EDT
for today's action
Ukeep asking 4then runaway from CommonCents as2 why?
https://investorshub.advfn.com/boards/read_person.aspx?membernum=157766
50 Shades of Avoidance pick 1 & try not to be scared
Clinical trials registers such as ClinicalTrials.gov and portals to trials registers such as the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) are increasingly used to identify ongoing or completed clinical trials.
ClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website
squatting dog DDers that can't dig enuff to pull up their successful clinical trials
would be easy to name the TSOI clinical trials that have been completed
The Racketeer Influenced and Corrupt Organizations Act (RICO) of 1970 seeks to strengthen the legal tools in evidence gathering by establishing new penal prohibitions and providing enhanced sanctions and new remedies for dealing with the unlawful activities of those engaged in organized crime.
The main factor in a RICO case is a “pattern” of criminal activity. There must be at least two acts of racketeering activity through the criminal enterprise within ten years for the RICO statute to apply
The actions most often invoked by RICO plaintiffs are mail fraud, wire fraud, and fraud in the sale of securities. However, innovative attorneys have also invoked other offenses, such as murder, kidnapping, gambling, arson, robbery, bribery, extortion, dealing in obscene matter, and drug trafficking.
> As of August 21, 2023, 3,324,82,767 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding.
Outstanding Shares 3,310,297,053 08/11/2023
Another Potential Positive https://www.businesswire.com/news/home/20230731364539/en/Therapeutic-Solutions-International-Prevention-Subsidiary-Campbell-Neurosciences-Receives-Notice-of-Allowance-on-Suicide-Prevention-Drug-Candidate
A notice of allowance is an office action from the Patent Office which informs the patent applicant that the claims in the patent application can be patented. To obtain the patent, an issue fee needs to be paid. About 4 to 6 weeks after payment of the issue fee, the Patent Office will grant the patent.
The Company is unable to file its quarterly report on Form 10-Q for the period ended June 30, 2023 within the prescribed time period due to its difficulty in completing and obtaining required financial and other information without unreasonable effort and expense. The 10-Q will be filed on or before the fifth calendar day following the extended due date not falling on a holiday or weekend, which would be August 21, 2023.
CommonCents Avoidance Irrefutable Facts Dixon'sOngoing_______s
Again, ask for then run away from
- and then we will compare notes later.
Events Timeline Screenshots Dixon's own words Very Telling
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171678401
Again
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172641415&txt2find=YTD
- and then we will compare notes later.
CommonCents who the PuckerUp Breath Mints R4 right Doc
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172641415
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171678401
Speaking of facts & irrefutable Ongoing_____s
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171678401
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171678401
Speaking of irrefutable facts my lil WebbyBoi
ControllabilityIam & OwnershipOf 4ALL2C
https://stocktwits.com/Websters2000
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172572977
YTD/DTC >533,704,893 08/11/23 Just the Facts squatting dawg
I'll save the BS for those Dumbass Dixon Minions, the good Doc himself
& the rest as it only takes CommonCents 2c who the Hypothetically challenged, squatting dawg & lies only crew R
Hey RunAwayBoi still wanna discuss facts that you can't handle or just continue 2B my lil female dawg ControllabilityIam
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172572315&txt2find=discuss
T/A Verified Discount’emDixon is responsible for the pps currently while his Ongoing _______s are/were his responsibility as well…along w/ Ichim
Watch L2 perhaps one's ignorance will be educated
Time& Sales confirm
August 21, 2023.
The Company is unable to file its quarterly report on Form 10-Q for the period ended June 30, 2023 within the prescribed time period due to its difficulty in completing and obtaining required financial and other information without unreasonable effort and expense. The 10-Q will be filed on or before the fifth calendar day following the extended due date not falling on a holiday or weekend, which would be August 21, 2023.
https://restem.com/. site still down
https://www.prweb.com/releases/RESTEM_and_JAR_of_Hope_Foundation_Announce_Strategic_Partnership_and_Clinical_Trial_Launch_of_Next_Generation_Cell_Therapy_for_Patients_with_Duchenne_Muscular_Dystrophy/prweb18866576.htm
https://www.prnewswire.com/news-releases/fda-approves-covid-19-trial-after-successful-emergency-use-of-umbilical-stem-cells-from-restem-301059158.html
btw Dixon trying to insert himself into said Court Case I personally appreciate as there is now legal paperwork w/ Dixon admitting to his Ongoing P3 ________s
OTCN dumps 3,498,148 13s Ask now 0013
CommonCents as2 why No addressing the misspelling of Timothy G. Dixon's legal name in any attempted court / legal filing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172632822
added a tequila shot w/
#ProofReading #IneptLegalCounsel? just needs to be addressed prior to
What are the rules for amicus briefs?
The only required sections of text of an amicus brief are the interests of the amicus, the summary of argument, the argument and a conclusion. Rule 37.5. Each of these should be a separate section, with a separate heading and text. The brief need not set forth the questions presented in the case.
MOTION FOR LEAVE TO FILE AMICI BRIEF
Pursuant to Federal Rule of Appellate Procedure 29(a) and Federal Circuit Rule 29(a), Amici Timothy 0. Dixon moves the Court for leave to file the attached Brief Amici Curiae in support of
upholding the Final Written Decision of the Patent Trial and Appeal Board ("PTAB"). The proposed
brief is attached to this Motion. In support of this Motion, Amici state as follows:
COMPANY OFFICERS & CONTACTS
Timothy G. Dixon President, CEO
1. An amicus curiae brief that brings to the attention of the Court relevant matter not already brought to its attention by the parties may be of considerable help to the Court. An amicus curiae brief that does not serve this purpose burdens the Court, and its filing is not favored.
OTCN lowers Ask to 0014 w/10k @ 12:02:46
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172613091
wishing most a pleasant weekend, now back to the sea for me
$TSOI PR day 59,013,034 Down (8.3%)
00115 14,285,714 avg 15:53:58
001182 2,004,000 avg 15:50:35
00116 4,697,181 avg 14:31:50
001182 5,000,000 avg 11:46:58
00115 14,285,714 avg 15:53:58
001182 2,004,000 avg 15:50:35
00116 4,697,181 avg 14:31:50
001182 5,000,000 avg 11:46:58
0012 2,500,000 12:28:21
0012 4,244,675 11:46:06
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/trades
YTD/DTC >533,704,893 08/11/23 Just Facts
I'll save the BS for those Dumbass Dixon Minions, the good Doc himself
& the rest as it only takes CommonCents 2c who the Hypothetically challenged & lies only crew R
Hey RunAwayBoi still wanna discuss facts that you can't handle
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172572315&txt2find=discuss
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172572841
Avoidance behaviors are any behaviors people use to escape or distract themselves from difficult thoughts, feelings, and situation
hey if you wanna post the breakdown on the shares , you don't have to hide it in a link to discuss it
What is the difference between a subsidiary and a spin-off?
A spin-off distributes shares of the new subsidiary to existing shareholders. A split-off offers shares in the new subsidiary to shareholders but they have to choose between the subsidiary and the parent company.
In a "spin-off," a parent company distributes shares of a subsidiary to the parent company's shareholders so that the subsidiary becomes a separate, independent company. The shares are usually distributed on a pro rata basis
A corporate spin-off is an operational strategy used by a company to create a new business subsidiary from its parent company. A spin-off occurs when a parent corporation separates part of its business operations into a second publicly traded entity and distributes shares of the new entity to its current shareholders.
9 days later Discount'emDixon increases SS again Outstanding Shares 3,310,297,053 08/11/2023 >67,242,714
Restricted 1,116,449,724 08/11/2023
Unrestricted 2,193,847,329 08/11/2023 >67,242,714
Held at DTC 2,092,029,804 08/11/2023 >15,873,016
YTD/DTC>533,704,893
Authorized Shares 4,500,000,000 08/02/2023
Outstanding Shares 3,243,054,339 08/02/2023
Restricted 1,116,449,724 08/02/2023
Unrestricted 2,126,604,615 08/02/2023
Held at DTC 2,076,156,788 08/02/2023
The Racketeer Influenced and Corrupt Organizations Act (RICO) of 1970 seeks to strengthen the legal tools in evidence gathering by establishing new penal prohibitions and providing enhanced sanctions and new remedies for dealing with the unlawful activities of those engaged in organized crime.
The main factor in a RICO case is a “pattern” of criminal activity. There must be at least two acts of racketeering activity through the criminal enterprise within ten years for the RICO statute to apply.
The actions most often invoked by RICO plaintiffs are mail fraud, wire fraud, and fraud in the sale of securities. However, innovative attorneys have also invoked other offenses, such as murder, kidnapping, gambling, arson, robbery, bribery, extortion, dealing in obscene matter, and drug trafficking.
CommonCents who the squatting DDog beatch is
Clinical trials registers such as ClinicalTrials.gov and portals to trials registers such as the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) are increasingly used to identify ongoing or completed clinical trials.
ClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website
squatting dog DDers that can't dig enuff to pull up their successful clinical trials
The Racketeer Influenced and Corrupt Organizations Act (RICO) of 1970 seeks to strengthen the legal tools in evidence gathering by establishing new penal prohibitions and providing enhanced sanctions and new remedies for dealing with the unlawful activities of those engaged in organized crime.
The main factor in a RICO case is a “pattern” of criminal activity. There must be at least two acts of racketeering activity through the criminal enterprise within ten years for the RICO statute to apply.
The actions most often invoked by RICO plaintiffs are mail fraud, wire fraud, and fraud in the sale of securities. However, innovative attorneys have also invoked other offenses, such as murder, kidnapping, gambling, arson, robbery, bribery, extortion, dealing in obscene matter, and drug trafficking.
https://www.businesswire.com/news/home/20230816569973/en/
Strange OTC Markets had not updated SS as of yesterday yet today it says 8/11/23
YTD/DTC>533,704,893 T/A Verifies Dixon responsible 4pps currently
Authorized Shares 4,500,000,000 08/11/2023
Outstanding Shares 3,310,297,053 08/11/2023 >67,242,714
Restricted 1,116,449,724 08/11/2023
Unrestricted 2,193,847,329 08/11/2023 >67,242,714
Held at DTC 2,092,029,804 08/11/2023 >15,873,016
uthorized Shares 4,500,000,000 08/02/2023
Outstanding Shares 3,243,054,339 08/02/2023
Restricted 1,116,449,724 08/02/2023
Unrestricted 2,126,604,615 08/02/2023
Held at DTC 2,076,156,788 08/02/2023
Held at DTC 1,558,324,911 12/27/22